A single-arm phase II DESTINY-Gastric02 study was given single-agent T-Dxd treatment for patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma who had progressed or intolerable after first-line treatment with trastuzumab. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.